ENANTA PHARMACEUTICALS, INC Proceeds from Sale of Available-for-sale Securities
ENANTA PHARMACEUTICALS, INC (ENTA) reported Proceeds from Sale of Available-for-sale Securities of $10.02 million for the 12-month period ending 2017-09-30, per its 10-K filed 2017-12-11.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2017-12-11
- ENANTA PHARMACEUTICALS, INC proceeds from sale of available-for-sale securities for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC proceeds from sale of available-for-sale securities for the quarter ending 2015-06-30 was $0.00.
- ENANTA PHARMACEUTICALS, INC proceeds from sale of available-for-sale securities for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC proceeds from sale of available-for-sale securities for the quarter ending 2014-12-31 was $2.21M, a 34.48% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC proceeds from sale of available-for-sale securities for fiscal 2017 was $10.02M.
- ENANTA PHARMACEUTICALS, INC proceeds from sale of available-for-sale securities for fiscal 2015 was $2.21M, a 73.76% decline from fiscal 2014.
- ENANTA PHARMACEUTICALS, INC proceeds from sale of available-for-sale securities for fiscal 2014 was $8.42M, a 54.43% increase from fiscal 2013.
- ENANTA PHARMACEUTICALS, INC proceeds from sale of available-for-sale securities for fiscal 2013 was $5.45M, a 65.38% decline from fiscal 2012.
| Period end | Proceeds from Sale of Available-for-sale Securities 3 month | Proceeds from Sale of Available-for-sale Securities 6 month | Proceeds from Sale of Available-for-sale Securities 9 month | Proceeds from Sale of Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2017-09-30 | $10.02M 10-K · filed 2017-12-11 | |||
| 2017-03-31 | $5.02M 10-Q · filed 2017-05-10 | |||
| 2015-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-11 | $0.00 derived: sum of 2 quarters · filed 2017-12-11 | $0.00 derived: sum of 3 quarters · filed 2017-12-11 | $2.21M 10-K · filed 2017-12-11 |
| 2015-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $0.00 derived: sum of 2 quarters · filed 2016-08-09 | $2.21M 10-Q · filed 2016-08-09 | $3.22M derived: sum of 4 quarters · filed 2016-12-09 |
| 2015-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10 | $2.21M 10-Q · filed 2016-05-10 | $3.22M derived: sum of 3 quarters · filed 2016-12-09 | $3.22M derived: sum of 4 quarters · filed 2016-12-09 |
| 2014-12-31 | $2.21M 10-Q · filed 2016-02-09 | $3.22M derived: sum of 2 quarters · filed 2016-12-09 | $3.22M derived: sum of 3 quarters · filed 2016-12-09 | $7.26M derived: sum of 4 quarters · filed 2016-12-09 |
| 2014-09-30 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-09 | $1.01M derived: sum of 2 quarters · filed 2016-12-09 | $5.05M derived: sum of 3 quarters · filed 2016-12-09 | $8.42M 10-K · filed 2016-12-09 |
| 2014-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-10 | $4.04M derived: sum of 2 quarters · filed 2015-08-10 | $7.41M 10-Q · filed 2015-08-10 | $10.41M derived: sum of 4 quarters · filed 2015-12-11 |
| 2014-03-31 | $4.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-08 | $7.41M 10-Q · filed 2015-05-08 | $10.41M derived: sum of 3 quarters · filed 2015-12-11 | $10.41M derived: sum of 4 quarters · filed 2015-12-11 |
| 2013-12-31 | $3.37M 10-Q · filed 2015-02-06 | $6.37M derived: sum of 2 quarters · filed 2015-12-11 | $6.37M derived: sum of 3 quarters · filed 2015-12-11 | $6.39M derived: sum of 4 quarters · filed 2015-12-11 |
| 2013-09-30 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | $3.00M derived: sum of 2 quarters · filed 2015-12-11 | $3.02M derived: sum of 3 quarters · filed 2015-12-11 | $5.45M 10-K · filed 2015-12-11 |
| 2013-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-08-12 | $18.00K derived: sum of 2 quarters · filed 2014-08-12 | $2.45M 10-Q · filed 2014-08-12 | $4.15M derived: sum of 4 quarters · filed 2014-12-11 |
| 2013-03-31 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-12 | $2.45M 10-Q · filed 2014-05-12 | $4.15M derived: sum of 3 quarters · filed 2014-12-11 | |
| 2012-12-31 | $2.44M 10-Q · filed 2014-02-13 | $4.14M derived: sum of 2 quarters · filed 2014-12-11 | ||
| 2012-09-30 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-11 | $15.75M 10-K · filed 2014-12-11 | ||
| 2012-06-30 | $14.05M 10-Q · filed 2013-08-12 | |||
| 2011-09-30 | $16.76M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |